A variant of estrogen receptor-α, hER-α36

Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling

ZhaoYi Wang, XinTian Zhang, Peng Shen, Brian W. Loggie, YunChao Chang, Thomas F. Deuel

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

The status of the 66-kDa human estrogen receptor-α (hER-α66) is a critical determinant in the assessment of the prognosis and in the design of treatment strategies of human breast cancer. Recently, we cloned the cDNA of an alternatively spliced variant of hER-α66, termed hER-α36; the predicted protein lacks both transcriptional activation domains of hER-α66 but retains its DNA-binding domain, partial dimerization, and ligand-binding domains and three potential myristoylation sites located near the N terminus. These findings thus predict that hER-α36 functions very differently from hER-α66 in response to estrogen signaling. We now demonstrate that hER-α36 inhibits the estrogen-dependent and estrogen-independent transactivation activities of hER-α66 and hER-β. We further demonstrate that hER-α36 is predominantly associated with the plasma membrane where it transduces both estrogen- and antiestrogen-dependent activation of the mitogen-activated protein kinase extracellular signal-regulated kinase signaling pathway and stimulates cell growth. We conclude that hER-α36 is a predominantly membrane-based, unique alternatively spliced variant of hER-α66 that acts as a dominant-negative effector of both estrogen-dependent and estrogen-independent transactivation functions signaled through hER-α66 and ER-β; it also transduces membrane-initiated estrogen-dependent activation of the mitogen-activated protein kinase extracellular signal-regulated kinase mitogenic signaling pathway. The estrogen and antiestrogen signaling pathways mediated by hER-α36 provide an alternative explanation for why some human breast cancers are resistant to and others are worsened by antiestrogen therapy; the data suggest that hER-α36 also may be an important marker to direct therapy in human breast cancers, and perhaps hER-α36 also may transduce estrogen-dependent signaling in other estrogen target tissues.

Original languageEnglish
Pages (from-to)9063-9068
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number24
DOIs
StatePublished - Jun 13 2006

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Estrogens
Membranes
Transcriptional Activation
Extracellular Signal-Regulated MAP Kinases
Breast Neoplasms
Mitogen-Activated Protein Kinases
Dimerization
Complementary DNA
Cell Membrane
Ligands

All Science Journal Classification (ASJC) codes

  • General
  • Genetics

Cite this

A variant of estrogen receptor-α, hER-α36 : Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. / Wang, ZhaoYi; Zhang, XinTian; Shen, Peng; Loggie, Brian W.; Chang, YunChao; Deuel, Thomas F.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 24, 13.06.2006, p. 9063-9068.

Research output: Contribution to journalArticle

@article{4f4376348b554fd49653254747a48b22,
title = "A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling",
abstract = "The status of the 66-kDa human estrogen receptor-α (hER-α66) is a critical determinant in the assessment of the prognosis and in the design of treatment strategies of human breast cancer. Recently, we cloned the cDNA of an alternatively spliced variant of hER-α66, termed hER-α36; the predicted protein lacks both transcriptional activation domains of hER-α66 but retains its DNA-binding domain, partial dimerization, and ligand-binding domains and three potential myristoylation sites located near the N terminus. These findings thus predict that hER-α36 functions very differently from hER-α66 in response to estrogen signaling. We now demonstrate that hER-α36 inhibits the estrogen-dependent and estrogen-independent transactivation activities of hER-α66 and hER-β. We further demonstrate that hER-α36 is predominantly associated with the plasma membrane where it transduces both estrogen- and antiestrogen-dependent activation of the mitogen-activated protein kinase extracellular signal-regulated kinase signaling pathway and stimulates cell growth. We conclude that hER-α36 is a predominantly membrane-based, unique alternatively spliced variant of hER-α66 that acts as a dominant-negative effector of both estrogen-dependent and estrogen-independent transactivation functions signaled through hER-α66 and ER-β; it also transduces membrane-initiated estrogen-dependent activation of the mitogen-activated protein kinase extracellular signal-regulated kinase mitogenic signaling pathway. The estrogen and antiestrogen signaling pathways mediated by hER-α36 provide an alternative explanation for why some human breast cancers are resistant to and others are worsened by antiestrogen therapy; the data suggest that hER-α36 also may be an important marker to direct therapy in human breast cancers, and perhaps hER-α36 also may transduce estrogen-dependent signaling in other estrogen target tissues.",
author = "ZhaoYi Wang and XinTian Zhang and Peng Shen and Loggie, {Brian W.} and YunChao Chang and Deuel, {Thomas F.}",
year = "2006",
month = "6",
day = "13",
doi = "10.1073/pnas.0603339103",
language = "English",
volume = "103",
pages = "9063--9068",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "24",

}

TY - JOUR

T1 - A variant of estrogen receptor-α, hER-α36

T2 - Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling

AU - Wang, ZhaoYi

AU - Zhang, XinTian

AU - Shen, Peng

AU - Loggie, Brian W.

AU - Chang, YunChao

AU - Deuel, Thomas F.

PY - 2006/6/13

Y1 - 2006/6/13

N2 - The status of the 66-kDa human estrogen receptor-α (hER-α66) is a critical determinant in the assessment of the prognosis and in the design of treatment strategies of human breast cancer. Recently, we cloned the cDNA of an alternatively spliced variant of hER-α66, termed hER-α36; the predicted protein lacks both transcriptional activation domains of hER-α66 but retains its DNA-binding domain, partial dimerization, and ligand-binding domains and three potential myristoylation sites located near the N terminus. These findings thus predict that hER-α36 functions very differently from hER-α66 in response to estrogen signaling. We now demonstrate that hER-α36 inhibits the estrogen-dependent and estrogen-independent transactivation activities of hER-α66 and hER-β. We further demonstrate that hER-α36 is predominantly associated with the plasma membrane where it transduces both estrogen- and antiestrogen-dependent activation of the mitogen-activated protein kinase extracellular signal-regulated kinase signaling pathway and stimulates cell growth. We conclude that hER-α36 is a predominantly membrane-based, unique alternatively spliced variant of hER-α66 that acts as a dominant-negative effector of both estrogen-dependent and estrogen-independent transactivation functions signaled through hER-α66 and ER-β; it also transduces membrane-initiated estrogen-dependent activation of the mitogen-activated protein kinase extracellular signal-regulated kinase mitogenic signaling pathway. The estrogen and antiestrogen signaling pathways mediated by hER-α36 provide an alternative explanation for why some human breast cancers are resistant to and others are worsened by antiestrogen therapy; the data suggest that hER-α36 also may be an important marker to direct therapy in human breast cancers, and perhaps hER-α36 also may transduce estrogen-dependent signaling in other estrogen target tissues.

AB - The status of the 66-kDa human estrogen receptor-α (hER-α66) is a critical determinant in the assessment of the prognosis and in the design of treatment strategies of human breast cancer. Recently, we cloned the cDNA of an alternatively spliced variant of hER-α66, termed hER-α36; the predicted protein lacks both transcriptional activation domains of hER-α66 but retains its DNA-binding domain, partial dimerization, and ligand-binding domains and three potential myristoylation sites located near the N terminus. These findings thus predict that hER-α36 functions very differently from hER-α66 in response to estrogen signaling. We now demonstrate that hER-α36 inhibits the estrogen-dependent and estrogen-independent transactivation activities of hER-α66 and hER-β. We further demonstrate that hER-α36 is predominantly associated with the plasma membrane where it transduces both estrogen- and antiestrogen-dependent activation of the mitogen-activated protein kinase extracellular signal-regulated kinase signaling pathway and stimulates cell growth. We conclude that hER-α36 is a predominantly membrane-based, unique alternatively spliced variant of hER-α66 that acts as a dominant-negative effector of both estrogen-dependent and estrogen-independent transactivation functions signaled through hER-α66 and ER-β; it also transduces membrane-initiated estrogen-dependent activation of the mitogen-activated protein kinase extracellular signal-regulated kinase mitogenic signaling pathway. The estrogen and antiestrogen signaling pathways mediated by hER-α36 provide an alternative explanation for why some human breast cancers are resistant to and others are worsened by antiestrogen therapy; the data suggest that hER-α36 also may be an important marker to direct therapy in human breast cancers, and perhaps hER-α36 also may transduce estrogen-dependent signaling in other estrogen target tissues.

UR - http://www.scopus.com/inward/record.url?scp=33745160700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745160700&partnerID=8YFLogxK

U2 - 10.1073/pnas.0603339103

DO - 10.1073/pnas.0603339103

M3 - Article

VL - 103

SP - 9063

EP - 9068

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 24

ER -